Willem H. Scheele

Optikira LLC engages in the development of novel therapeutics to prevent cell death diseases such as retinitis pigmentosa, diabetes, and amyotrophic lateral sclerosis. The company was founded by Bradley Backes, Dustin Maly, Scott Oakes, and Feroz Papa in 2015 and is headquartered in Cleveland, OH.

Part of NIKE, Inc., Professional Services is an American marine services company that offers top-notch maritime solutions ensuring excellence in every project. The company also provides marine services in UAE for seamless and reliable options. Professional Services LLC takes pride in the delivery of the most reliable and high-quality underground services work in Emirates. Professional Services was acquired by Exds, Inc. from Network-1 Technologies, Inc on February 10, 2000 for $4 million.

Genentech Ventures (Genentech Ventures) is a venture capital firm founded in 1900. The firm is headquartered in South San Francisco, CA.

Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland.

The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA.

T-Cure Bioscience, Inc. is an innovative immuno-oncology company based in Sherman Oaks, CA. The private company maintains a pipeline of TCR under clinical and pre-clinical development targeting HERV-E, KK-LC-1, NY-ESO-1, and other antigens associated with solid tumors of significant unmet medical needs, including kidney cancer, breast cancer, lung cancer, gastric cancer, ovarian cancer, liver cancer, pancreatic cancer, sarcoma, and glioblastoma. The CEO of the company is Gang Zeng.

Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom.

Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA.

The Friedreich's Ataxia Research Alliance provides patient registry services. The private company is based in Downingtown, PA.

Iterum Therapeutics US Holding Ltd. operates as a clinical-stage pharmaceutical company. The company was founded in 2018 and is headquartered in Chicago, IL.

NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom.

Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools.

Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Avoro Ventures LLC (Avoro Ventures) is a venture capital subsidiary of Avoro Capital Advisor LLC founded in 2020. The firm is headquartered in New York.

Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir.

Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York.

Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA.

Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation.

Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA.

Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD.

Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH.

Keystone Heart Ltd. engages in the development and manufacture of cerebral embolic protection devices that aim to reduce the risk of stroke, neurocognitive decline, and dementia caused by brain damage associated with cardiovascular procedures. The company was founded by Dov V. Shimon in 2004 and is headquartered in Caesarea, Israel.

Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.